IL6 and metabolic dysfunction-associated steatotic liver disease: Hadinia et al. [22] reported remarkably higher IL-1β and IL-6 in NASH patients compared to both NAFLD and controls, thus indicating that the clinical data of the early stage of NAFLD are similar to healthy subjects, and the development of steatosis and inflammation occurs as a result of increased pro-inflammatory mediators in NASH patients [22].